NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma-Reference-Cited by-同舟云学术

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma

Published:2018-10-10 Issue:22 Volume:124 Page:4332-4341
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Tarhini Ahmad A.¹²,Frankel Paul³,Ruel Christopher³,Ernstoff Marc S.⁴,Kuzel Timothy M.⁵,Logan Theodore F.⁶,Khushalani Nikhil I.⁷,Tawbi Hussein A.⁸,Margolin Kim A.³,Awasthi Sanjay³,Butterfield Lisa H.¹⁹¹⁰¹¹,McDermott David¹²,Chen Alice¹³,Lara Primo N.¹⁴,Kirkwood John M.¹

Affiliation:

1. University of Pittsburgh Medical Center Hillman Cancer Center; University of Pittsburgh; Pittsburgh Pennsylvania

2. Department of Hematology and Oncology; Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center; Cleveland Ohio

3. City of Hope National Medical Center; Duarte California

4. Roswell Park Comprehensive Cancer Center; Buffalo New York

5. Rush University Medical Center; Chicago Illinois

6. Indiana University Melvin and Bren Simon Cancer Center; Indianapolis Indiana

7. Moffitt Cancer Center; Tampa Florida

8. The University of Texas MD Anderson Cancer Center; Houston Texas

9. Department of Medicine; University of Pittsburgh School of Medicine; Pittsburgh Pennsylvania

10. Department of Surgery; University of Pittsburgh School of Medicine; Pittsburgh Pennsylvania

11. Department of Immunology; University of Pittsburgh School of Medicine; Pittsburgh Pennsylvania

12. Beth Israel Deaconess Medical Center; Boston Massachusetts

13. Cancer Therapy Evaluation Program; National Cancer Institute; Bethesda Maryland

14. University of California at Davis Comprehensive Cancer Center; Sacramento California

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31734/fullpdf

Reference30 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Immunotherapy of cancer in 2012;Kirkwood;CA Cancer J Clin,2012

3. Interleukin-2: inception, impact, and implications;Smith;Science,1988

4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999

5. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update;Atkins;Cancer J Sci Am,2000

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

2. Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma;Cancers;2023-12-15

3. Safety and efficacy of autogeneic NKT cells infusion in advanced melanoma patients: a Phase I clinical trial;2023-11-08

4. Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data;Contemporary Clinical Trials;2023-02

5. The role of angiogenesis in melanoma: Clinical treatments and future expectations;Frontiers in Pharmacology;2022-12-15